External ear canal squamous cell carcinoma

• Enhancing soft-tissue mass centered in the external auditory canal with irregular or aggressive bone destruction
• Focal dural thickening and enhancement suggesting medial/intracranial spread
• Asymmetric cranial nerve (CN VII or V3) enlargement or enhancement indicating perineural disease

• On CT: irregular cortical erosion progressing to full-thickness destruction of canal walls is the hallmark, best depicted on thin-section temporal-bone CT with multiplanar bone reconstructions.
• On MRI: the primary mass is typically iso- to mildly hypointense on T1 and mildly to heterogeneously hyperintense on T2, with heterogeneous enhancement in advanced disease; marked T2-bright nonenhancing material likely represents trapped fluid rather than viable tumor.
• Contrast enhancement helps distinguish viable tumor from nonenhancing middle-ear fluid, mastoid secretions, or cholesteatoma; early small lesions may enhance homogeneously while advanced SCC shows heterogeneous enhancement with necrosis.
• Medial extension across the tympanic membrane into the middle ear, otic capsule, petrous apex, carotid canal, jugular foramen, or skull base follows the low-resistance pathway and appears as direct enhancing tumor continuity on contrast-enhanced sequences.
• Intracranial spread through the tegmen produces focal dural thickening and enhancement in the middle cranial fossa (the earliest MRI sign), loss of fat planes, nodular dural disease, or contiguous temporal-lobe invasion.
• Perineural disease along CN VII or auriculotemporal (V3) nerves manifests as asymmetric nerve enlargement or enhancement, foraminal fat loss, facial-canal or foraminal enlargement, and subsequent denervation changes.
• Inferior extension through the canal floor into infratemporal or upper neck soft tissues is a common extra-temporal spread route, best evaluated on coronal MRI with fat suppression to define the deep soft-tissue and parapharyngeal extension.
• Anterior and posterior extensions involve the TMJ/masticator space/parotid region or mastoid/postauricular tissues respectively; extensive soft-tissue involvement (greater than 0.5 cm extra-canal extension) signifies T4 disease.

• Necrotizing otitis externa (skull-base osteomyelitis): may be radiologically indistinguishable from SCC, with inflammatory tissue in the EAC, subtemporal fat-plane obliteration, and skull-base marrow abnormality; culture, inflammatory markers, treatment response, and deep biopsy are essential to differentiate, as the two may coexist.
• EAC cholesteatoma: presents as an EAC soft-tissue mass with focal erosion (often inferior wall) and intramural bone fragments/sequestra; non-echo-planar DWI hyperintensity supports keratin; SCC is favored by solid enhancement, infiltrative extra-canal soft tissue, perineural disease, and nodal involvement.
• EAC keratosis obturans: typically a keratin plug with smooth generalized canal widening, often bilateral and in younger patients; focal destructive erosion or invasive enhancing soft tissue is atypical and should prompt reconsideration for malignancy.
• Chronic otitis externa/granulation/medial canal fibrosis: shows circumferential soft-tissue thickening or stenosis without a discrete invasive mass and minimal aggressive bone destruction; persistent focal enhancement, ulceration, progressive erosion, or treatment failure warrant biopsy.
• Ceruminous adenocarcinoma or adenoid cystic carcinoma: often a relatively well-defined enhancing lesion arising in the cartilaginous EAC; adenoid cystic carcinoma has strong perineural propensity; histology is definitive and exclusion of direct extension from parotid primary is essential.
• Parotid or middle-ear malignancy: establish the epicenter; primary EAC SCC typically begins in the canal and spreads outward, whereas parotid masses show posterior extension into the cartilaginous canal or middle-ear tumors show secondary tympanic membrane/EAC invasion.

Explicitly describe the individual structures involved (e.g., "full-thickness erosion of the posterior canal wall with middle-ear involvement and focal dural thickening") rather than reporting only a T category, because the broad T4 group contains tumors with substantially different surgical options and prognoses; this level of anatomic specificity directly guides surgical planning and margin assessment.

• SCC versus necrotizing otitis externa is the highest-risk diagnostic pitfall: both produce EAC soft tissue, aggressive osseous erosion, skull-base extension, cranial neuropathy, and enhancement; apparent infection must not end the workup when there is a focal mass, unexplained progressive destruction, bleeding, poor treatment response, or discordance between clinical and imaging findings.
• SCC versus EAC cholesteatoma: sequestered intramural bone fragments and marked non-echo-planar diffusion restriction favor cholesteatoma, whereas enhancing invasive soft tissue, perineural spread, and metastatic nodes favor carcinoma, but imaging alone may remain indeterminate and require biopsy confirmation.
• Both CT and MRI can underestimate or overestimate tumor extent, particularly at the interface of tumor with inflammatory change; imaging findings must be correlated with otoscopy, biopsy site, symptoms, and multidisciplinary surgical assessment rather than interpreted in isolation.
• CT cannot reliably distinguish tumor from granulation tissue, cholesteatoma, inflammatory mucosal thickening, or retained secretions; contrast-enhanced MRI with diffusion imaging and careful assessment of enhancement pattern is essential for accurate tissue characterization.